Jim Cramer Likes Bristol-Myers Over Gilead

Katherine Ross

Gilead announced that its remdesivir drug, which is being used to treat the coronavirus, will cost around $390 a vial. Gilead, in a press release, noted that--based on current treatment patterns--this will cost consumers around $2,340 a patient in developed countries.

However, for those with private insurance, the cost will be $520 vial and a five-day treatment would cost patients $3,120.

In an open letter, CEO Daniel O’Day said Gilead will provide remdesivir “well below” the value that it has so far proven to provide in treating patients afflicted with Covid-19, the respiratory illness contracted through exposure to the novel coronavirus.

“In normal circumstances, we would price a medicine according to the value it provides,” O’Day said in the letter. However, “To ensure broad and equitable access at a time of urgent global need, we have set a price for governments of developed countries of $390 per vial.”

"There is no playbook for how to price a new medicine in a pandemic," said O’Day.

Remdesivir is a broad-spectrum antiviral medication administered via injection that has proven effective at helping patients with severe symptoms of Covid-19 recover. While Gilead has received emergency use authorization from the Food and Drug Administration, it has not yet been formally approved as a coronavirus treatment.

So, what does this mean for the stock of Gilead?

Jim Cramer said that he's still not a fan of the stock.

You can follow Jim Cramer and Katherine Ross on Twitter at @JimCramer and @byKatherineRoss. 

Read more from Katherine Ross here.

Watch More of the Latest Videos on TheStreet and Jim Cramer

Enter your email to register or login. Registration information may be shared with advertising partners in accordance with our Privacy Policy.

Stock Picks